Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Mental Health topic
No spam. Unsubscribe anytime.
Committee advances bill to require insurer coverage for PANS/PANDAS treatment after families testify about high costs
Summary
House Bill 408, sponsored by Representative Dickerson, was reported favorably after emotional testimony from families and clinicians describing pediatric acute-onset neuropsychiatric syndrome (PANS/PANDAS), treatment paths including IVIG, and coverage denials; insurers cautioned about clinical consensus and recommended specialty cohort review.
House Bill 408, carried by Representative K. Dickerson, would require health-insurance coverage for treatment of pediatric acute-onset neuropsychiatric syndrome (PANS/PANDAS) and related conditions. The House Insurance Committee voted to report the bill favorably after extensive testimony from affected families, clinicians and insurers.
Representative K. Dickerson said families’ out-of-pocket costs for therapies and infusions can be substantial and that some states have enacted coverage measures. Parents and children provided detailed testimony. Caitlin Giuffrida described her daughter’s acute neurological decline and the medical pathway the family pursued, including outpatient antibiotics and, later, an intravenous immunoglobulin (IVIG) infusion that the family paid about $10,500 to receive; she said TRICARE denied part of the claim for lack of preauthorization. Her daughter’s father, Eric Bridal, described TRICARE covering some physician visits but not the IVIG when preauthorization could not be obtained due to urgency.
Dr. Giuffrida and others described symptom onset, psychiatric misdiagnosis, and the combination of antibiotics, steroids and IVIG used in some cases. Families said early treatment made a material difference in children’s functioning; one parent said the child regained school performance after treatment.
Jeff Drazda of the Louisiana Association of Health Plans urged caution, citing the March 2025 American Academy of Pediatrics guidance that does not broadly recommend IVIG for all PANS cases and suggests multidisciplinary specialty involvement. Drazda said the evidence base is mixed and that insurers rely on recognized clinical practice guidelines when deciding coverage.
Representative Dickerson closed asking for favorable passage and offered to continue discussions with insurers about implementation. The committee reported HB 408 favorably; members said they would work with stakeholders on scope and potential guardrails such as specialty review teams or provider verification to reduce inappropriate utilization.
Why it matters: Testimony emphasized high clinical urgency, family financial strain and potential severe outcomes without treatment; insurers stressed the lack of uniform national guidance and urged structured specialty review. The committee’s action advances the bill toward House debate, with follow-up negotiations expected on clinical criteria and oversight.
